Modulation of thymidine phosphorylase by neoadjuvant chemotherapy in primary breast cancer
β Scribed by Toi, M; Bando, H; Horiguchi, S; Takada, M; Kataoka, A; Ueno, T; Saji, S; Muta, M; Funata, N; Ohno, S
- Book ID
- 109998077
- Publisher
- Nature Publishing Group
- Year
- 2004
- Tongue
- English
- Weight
- 143 KB
- Volume
- 90
- Category
- Article
- ISSN
- 0007-0920
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
Neoadjuvant chemotherapy in breast cancer was developed in the 1970s and is now used in patients with locally advanced or early resectable breast cancer. Early administration of systemic chemotherapy before local treatment in locally advanced breast cancer and early resectable breast cancer is inten
In order to know whether neoadjuvant chemotherapy would change the hormonal receptor status of primary breast cancer, 10 patients with locally advanced breast cancer treated with neoadjuvant CEF (endoxan , epirubicin, 5-fluorouracil) were studied. Tissue was obtained by incisional biopsy before chem
## Abstract Thymidine phosphorylase (TP), also known as βplateletβderived endothelial cell growth factorβ (PDβECGF), is an enzyme, which is upregulated in a wide variety of solid tumors including breast and colorectal cancers. TP promotes tumor growth and metastasis by preventing apoptosis and indu